Epilepsy

Here's some of what is coming soon to NeurologyLive® this week.

The division director of pediatric neurology, and director of the pediatric sleep program at Cohen, Children's Medical Center, Northwell Health, spoke about sudden unexpected death in epilepsy and sleep at the 2022 AES Conference. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 16, 2022.

Almost 3 years since the beginning of the pandemic, continuous research efforts have begun to paint a better picture of the impact the virus has on the brain and the central nervous system.

The division director of pediatric neurology, and director of the pediatric sleep program at Cohen Children's Medical Center of Northwell Health, spoke about the association between sleep disorders and pediatric epilepsy at the 2022 AES annual meeting. [WATCH TIME: 3 minutes]

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

The pediatric epilepsy specialist at Weill Cornell Medicine in New York City spoke on how meetings such as the 2022 AES Conference bring clinicians together as well as how parents motivate them to advance pediatric epilepsy research. [WATCH TIME: 6 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

The assistant professor of neurology at Massachusetts General Hospital and Harvard Medical School spoke about the high risk of epilepsy for the older population at the 2022 AES annual meeting. [WATCH TIME: 1 minute]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Alzheimer disease and related dementias.

In a recent time-to-event analysis based on two clinical trials of patients with Dravet syndrome results demonstrated an overall reduction in seizure burden with fenfluramine.

Neurology News Network for the week ending December 10, 2022. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 9, 2022.

The professor of neurology at Washington University School of Medicine in St. Louis spoke about the field of newborn sleep and epilepsy based on a special lecture from the 2022 AES annual meeting. [WATCH TIME: 3 minutes]

After nearly a year of treatment with fenfluramine, more than half of patients with Lennox-Gastaut syndrome demonstrated at least a 50% reduction in drop seizure frequency.

A qualitative study presented at the 2022 AES annual meeting showed that effective communication between clinicians and caregivers of patients with dravet syndrome improves care.

The professor of neurology at Washington University in St. Louis, spoke about sleep-wake patterns in epilepsy based on a special lecture from the 2022 AES Annual meeting. [WATCH TIME: 6 minutes]

Martina Bebin, MD, MPA, professor of neurology, University of Alabama at Birmingham Epilepsy Center, discussed Infantile Spasms Awareness Week, the strides made within the field, and the emphasis on early and accurate diagnosis.

The associate professor of neurology at the University of Calgary spoke about advancing epilepsy care through patient-oriented research at the 2022 AES Annual Meeting. [WATCH TIME: 6 minutes]

Retrospective analysis of a group of individuals with stroke suggests that nonconvulsive acute symptomatic seizures are associated with long-term use of antiseizure medications, providing key data in guiding therapy use in this population.

Lucretia Long, APRN-CNP, an associate clinical professor of neurology at OSU Wexner Medical Center, offered her perspective on the benefits of having multiple specialists available to provide comprehensive care to patients.

Notably, though, cenobamate treatment was associated with weight reductions among patients who were categorized as overweight and obese, but not in those who were underweight or normal weight.

The associate professor of neurology at Wayne State University in Detroit, Michigan, spoke about expensive antiseizure medications for epilepsy along with spending for Medicare and Medicaid at the 2022 AES Annual Meeting. [WATCH TIME: 4 minutes]

The investigational therapy from Xenon Pharmaceuticals showed marked reductions in monthly seizure frequency from months 14 to 20, with consistent safety and good retention rates.

The professor of neurology and pediatrics at the University of Alabama at Birmingham Epilepsy Center provided perspective on the strides made with detection and treatment of infantile spasms. [WATCH TIME: 3 minutes]